China Biopharmaceutical's southern HQ settled in Huangpu

China Biopharmaceutical's southern headquarters recently established itself on Guangzhou International Bio Island, aligning with the national strategy for the Guangdong-Hong Kong-Macao Greater Bay Area. 

This initiative is intended to facilitate the introduction and domestic clinical transformation of leading global pharmaceutical pipelines, establishing a dual circulation system that operates both domestically and internationally.

The southern HQ has introduced several international clinical projects, including treatments for non-alcoholic steatohepatitis, the Softhale inhalation medicine delivery platform, and new-generation cancer immunotherapies.

In collaboration with its overseas subsidiary, invoX, China Biopharmaceutical plans to introduce leading global pharmaceutical pipelines, accelerate the research and development of innovative drugs, and enhance the internationalization level of new medicine development in Huangpu, aspiring to transform Guangzhou into a global hub for biopharmaceutical innovation and industrial development.

Share - WeChat